Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALY688ER
- Development stage
- Phase 1
- Lead developer
- Allysta Pharmaceuticals
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
ALY688ER is a sustained-release systemic formulation of the peptide drug ALY688 designed for subcutaneous administration. It is an adiponectin mimetic and acts as an agonist at adiponectin receptors (
- Other names
- ALY688ERALY-688ERALY 688ERsustained release systemic formulation of ALY688
02
Targets
ADIPOR1 (Adiponectin receptor 1)ADIPOR2 (Adiponectin receptor 2)AdipoR (Adiponectin receptor)
Beyond the preview
Go deeper on ALY688ER.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALY688ER.